Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
23.08%
operating margin TTM
18.1%
revenue TTM
120.44 Million
revenue per share TTM
1.5$
valuation ratios | |
|---|---|
| pe ratio | 1.74 |
| peg ratio | 0.01 |
| price to book ratio | -121.47 |
| price to sales ratio | 0.38 |
| enterprise value multiple | 3.09 |
| price fair value | -121.47 |
profitability ratios | |
|---|---|
| gross profit margin | 99.33% |
| operating profit margin | 18.1% |
| pretax profit margin | 23.24% |
| net profit margin | 23.08% |
| return on assets | 26.44% |
| return on equity | -146.84% |
| return on capital employed | 71.91% |
liquidity ratio | |
|---|---|
| current ratio | 1.25 |
| quick ratio | 1.25 |
| cash ratio | 0.44 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 8.20 |
| days of payables outstanding | 428.86 |
| cash conversion cycle | -420.65 |
| receivables turnover | 44.51 |
| payables turnover | 0.85 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | -20.58 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 1.05 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -9.19 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.02 |
| cash per share | 1.19 |
| operating cash flow per share | -1.02 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -9.19 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -278.16 |
Frequently Asked Questions
When was the last time CytomX Therapeutics, Inc. (NASDAQ:CTMX) reported earnings?
CytomX Therapeutics, Inc. (CTMX) published its most recent earnings results on 07-11-2024.
What is CytomX Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. CytomX Therapeutics, Inc. (NASDAQ:CTMX)'s trailing twelve months ROE is -146.84%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. CytomX Therapeutics, Inc. (CTMX) currently has a ROA of 26.44%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CTMX's net profit margin stand at?
CTMX reported a profit margin of 23.08% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CTMX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.25 in the most recent quarter. The quick ratio stood at 1.25, with a Debt/Eq ratio of -20.58.